FDA Advisors Vote for Restrictions on Opdivo, Keytruda, Similar Stomach Cancer Drugs
Panel of independent experts found little to no evidence that these drugs extend the lives of stomach cancer patients.
Panel of independent experts found little to no evidence that these drugs extend the lives of stomach cancer patients.
Scientists will meet next month, to make recommendations to the FDA about whether the risks with Opdivo, Keytruda and Yervoy outweigh benefits for stomach cancer treatment.